Stratagene Licenses Rights to MicroRNA Sequences from Max Planck | GenomeWeb
NEW YORK (GenomeWeb News) - Stratagene said today that it has licensed rights to more than 150 microRNA sequences from Max Planck Innovation, the commercial arm of the Max Planck Society.
 
Under the agreement, Stratagene purchased co-exclusive rights to use the sequences to make and sell molecular diagnostic kits based on its FullVelocity platform.
 
The company said it is particularly interested in the use of microRNAs for cancer biomarker applications.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.